Tropical spastic paraparesis primary prevention

Tropical spastic paraparesis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Tropical spastic paraparesis from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Tropical spastic paraparesis primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Tropical spastic paraparesis primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Tropical spastic paraparesis primary prevention
CDC on Tropical spastic paraparesis primary prevention
Tropical spastic paraparesis primary prevention in the news
Blogs on Tropical spastic paraparesis primary prevention
Directions to Hospitals Treating Tropical spastic paraparesis
Risk calculators and risk factors for Tropical spastic paraparesis primary prevention

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Blood transfusion products are screened for HTLV-1 antibodies.